Q2 FY24 Financial Highlights
Other Markets: Key Highlights
EU
Steady performance in developed markets
EU
•
Growth driven by higher
LuforbecⓇ and tender sales
Strong growth in Germany and UK
Completed Medisol acquisition in
France
South Africa
Brazil
Emerging Markets
LUPIN
BRL 74 mn sales in Q2 FY24 (growth
of 6% YoY)
Rank 4th in reference market³
7th largest generics player¹
Mexico
Revenues of MXN 83 mn, 63% YoY
decline due to impact of stock-outs
Revenues of ZAR 341 mn up by
16% QoQ
4th largest generics player²
Australia
Philippines
33% YoY growth driven by renal and
women's health
New launches from SCP portfolio
API + Global
Institutional
.
•
API revenues grew 7% YoY due to increase in sales of 7ACCA and Levetiracetam
Global Institutional business growth driven by higher Anti-TB and ARV sales
Note:
1. IQVIA MAT Sept 23 by sales
2. IQVIA Midas Sales Audit Mar-23
3. IQVIA MAT Sept-23 units
10View entire presentation